Simplify ADC Development with AJICAP™
AJICAP™ supports bioconjugate development from early evaluation through clinical manufacturing using an adaptable engagement model. The combination of early-stage evaluation, technology licensing, and flexible manufacturing options provides an efficient pathway from concept to clinical supply.
Remove Constraints at Every Step of the Process
AJICAP™ provides a flexible pathway from early evaluation through clinical manufacturing. Our team supports conjugation development, analytical characterization, and technology transfer, with multiple pathways to GMP manufacturing through qualified partners.
Inquiry & Evaluation
Initial technical discussion
Feasibility assessment
Sample preparation
AJICAP™ conjugation and linker technology evaluation
Development & Optimization
Conjugation process development
Linker-payload optimization
Analytical characterization
Technology selection and development planning
Technology Transfer & Manufacturing Preparation
Process transfer package
Analytical method transfer
Manufacturing strategy development
Technology transfer to a qualified partner CDMO
Clinical Manufacturing & Supply
GMP manufacturing through qualified CDMO partners
Clinical supply support
Stability studies and release testing
Ongoing technical support
How AJICAP™ Works with Manufacturing Partners
We provide AJICAP™ conjugation and linker technologies together with process development, analytical support, and technology transfer expertise. For GMP manufacturing, established processes can be transferred to a qualified AJICAP™ partner CDMO or another qualified manufacturing partner, with our experts providing technical support through implementation. This flexible model allows customers to select the manufacturing pathway that best fits their program needs.
Ajinomoto Bio-Pharma Services
AJICAP™ Technology Owner
Process development and optimization
Technology transfer package and technical support
Ongoing manufacturing support
Partner CDMO
Technology transferred for manufacturing
Conjugation process implementation and scale-up
Manufacturing preparation
GMP manufacturing and supply
Ready to Move Forward?
From first conjugate through clinical supply, explore the pathway that fits your program.
Frequently Asked Questions
How long does an AJICAP™ engagement typically take?
Engagement timelines vary depending on program scope and manufacturing requirements. For early-stage evaluation, AJICAP™ sample preparation can typically be completed within two weeks of receiving the necessary materials, enabling rapid assessment of conjugation feasibility. Development, technology transfer, and clinical manufacturing timelines are determined on a project-specific basis, taking into account program requirements, manufacturing strategy, and the selected CDMO partner.
Does Ajinomoto Bio-Pharma Services license AJICAP™ technology?
Yes. Ajinomoto Bio-Pharma Services typically provides AJICAP™ through a technology licensing model, enabling flexible use of AJICAP™ conjugation and linker technologies across customer programs. Prior to licensing, proof-of-concept studies and sample preparation can be supported depending on customer needs.
Who manufactures AJICAP™?
Ajinomoto Bio-Pharma Services provides the AJICAP™ conjugation and linker technologies, together with process development, analytical support, and technology transfer. GMP manufacturing is performed by qualified third-party CDMO partners or customer-selected manufacturing partners, providing flexibility in manufacturing strategy and supply chain planning.
Does Ajinomoto Bio-Pharma Services provide analytical support for AJICAP™?
Ajinomoto Bio-Pharma Services provides analytical characterization and process development support for conjugate evaluation and development. Available services for AJICAP™ include DAR analysis, stability assessment, and related characterization studies. Analytical support is primarily provided for research and development activities and can support efficient development and technology transfer.